BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 4 comparable calls have settled; 50% reached the published sell target. Information only, not financial advice.
Mid-channel, rising on both timeframes
Price is between the two trend lines. Nothing to act on yet.
The next few months are read from the last 9 months, the stretch whose swings the lines actually follow, because the last 12 months alone do not contain enough turns to fit reliably (61% against 89%). The last 12 months stay as context: rising, +49% a year. The target of US$67.49 is below the nearest ceiling (US$69.89), so it does not depend on a breakout. What would overturn this: a close below US$48.47 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 9 months read from
- US$48.47 – US$69.92 Rising channel, +25% a year
- 12 months
- US$57.28 – US$69.89 Rising channel, +49% a year
- Position in that channel
- 71% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$62.49
level as at 6 Oct 2026
Our target
US$67.49
by 3 Nov 2026
Projected move
8.0%
gross, before costs
Price sits between our buy level and our target.
The lines are drawn where this stock has actually turned: 4 touches on the ceiling, 4 on the floor, each fitted to the slope that catches the most of them. Buying one average daily range below its 50-day mean, on heavier volume than usual and while it is still above its 200-day mean, has come up 791 times; measured against the 6% floor — the least a call has to be worth to be worth making, not what it aims at — 73% cleared it, typically in 34 days, with price going about 5% against the entry along the way (63% in the worst case we have on record). Trades that have not reached the target within 3 months are counted as misses, whatever they are worth at the time. The prices above are this stock’s own — its average, its volatility — but the setup is the same one we apply everywhere: derived on eight unrelated tickers, then confirmed on 87 others it was never fitted to. We deliberately do not tune it to each stock: doing so scores worse on history the tuning never saw — 58% against 71% — because it fits the past rather than the future. On this stock the setup has come up 6 times so far, reaching target 67% of the time — too few to mean much on its own. The sell price comes from where this stock is projected to be, not from a minimum worth taking: the fitted path reaches 16% above the entry within 90 days, and of the sizes that path supports, 8% is the one that has returned the most per day of money tied up here — measured over 145 stretches of this stock’s own history, since the published entry itself is too rare here to size a target from, reached 59% of the time, typically in 28 days. Smaller sizes got there sooner but paid less for the weeks they used; larger ones need a break above the projected ceiling, which is not the base case. The date published is whichever is later: that typical time, or the day the projected path itself reaches the price. It is a prediction, so it can be revised: if the run tops out before it gets there, the target is cut to what is actually on the table and you are told the same day. An ordinary pullback is not treated as topping out — those go on to make a new high about 8 times in 10, so they are ridden through. What triggers the revision is price closing below its 50-day trend and staying there, after which the odds of recovery fall to roughly 3 in 10.
On this stock's own history these rules produced 4 settled calls, of which 2 reached target (50%), with an average best move of 4.9%. See the full record.
- Upper line touches
- 4
- Lower line touches
- 4
- Fit confidence
- 89%
- Fitted
- 16 Sept 2026
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher Boerner
- Employees
- 32,500
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$130.00B
- Enterprise value
- —
- Beta
- 0.23
- Avg volume
- 11.14M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 42.52-68.64
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.